Come up with a name for your new list and we'll add to it:
Andromeda Biotech raised a round of funding on June 14, 2007. Investors include
Clal Biotechnology Industries.
Andromeda Biotech is focused on the development of an innovative treatment for autoimmune diabetes. The company's lead product, DiaPep277 is currently in Phase III clinical trials for treating type 1 …